1. Home
  2. LRCX vs AZN Comparison

LRCX vs AZN Comparison

Compare LRCX & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lam Research Corporation

LRCX

Lam Research Corporation

HOLD

Current Price

$214.64

Market Cap

206.9B

Sector

Technology

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$94.46

Market Cap

283.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRCX
AZN
Founded
1980
1992
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
206.9B
283.9B
IPO Year
N/A
1993

Fundamental Metrics

Financial Performance
Metric
LRCX
AZN
Price
$214.64
$94.46
Analyst Decision
Buy
Strong Buy
Analyst Count
26
2
Target Price
$165.25
N/A
AVG Volume (30 Days)
12.0M
5.0M
Earning Date
01-28-2026
02-05-2026
Dividend Yield
0.47%
1.64%
EPS Growth
46.65
45.02
EPS
4.53
6.02
Revenue
$19,591,788,000.00
$58,127,000,000.00
Revenue This Year
$17.62
$11.40
Revenue Next Year
$12.76
$6.06
P/E Ratio
$48.64
$15.56
Revenue Growth
25.66
13.52
52 Week Low
$56.32
$61.24
52 Week High
$222.58
$96.51

Technical Indicators

Market Signals
Indicator
LRCX
AZN
Relative Strength Index (RSI) 71.49 60.32
Support Level $195.04 $93.22
Resistance Level $222.58 $96.51
Average True Range (ATR) 6.75 1.49
MACD 3.58 0.07
Stochastic Oscillator 84.68 70.63

Price Performance

Historical Comparison
LRCX
AZN

About LRCX Lam Research Corporation

Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Share on Social Networks: